150 related articles for article (PubMed ID: 24882974)
1. Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study.
Hong JW; Lee S; Kim DC; Kim KH; Song KH
Ann Dermatol; 2014 Apr; 26(2):195-202. PubMed ID: 24882974
[TBL] [Abstract][Full Text] [Related]
2. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
4. Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.
Jamerson T; Rebecca VW; Aguh C
J Natl Med Assoc; 2022 Feb; 114(1):7-11. PubMed ID: 34509302
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity and Usefulness of VE1 Immunohistochemical Staining in Acral Melanomas with
Suh MS; Choi YD; Lee JB; Lee SC; Won YH; Yun SJ
Ann Dermatol; 2018 Oct; 30(5):556-561. PubMed ID: 33911478
[TBL] [Abstract][Full Text] [Related]
6. BRAF Mutation Analysis in Primary Acral Melanoma of 41 Cases from South of Iran.
Sari Aslani F; Safaee A; Akbarzadeh Jahromi M; Karami L
Iran J Pathol; 2021; 16(4):370-375. PubMed ID: 34567185
[TBL] [Abstract][Full Text] [Related]
7. Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma.
Ruiz-Garcia E; Matus-Santos JA; Guadarrama-Orozco JA; Alvarez-Avitia MA; Aguilar-Ponce JL; Fernandez-Figueroa E; Maldonado-Mendoza J; Lopez-Camarillo C; Marchat LA; Lino-Silva S; Cuellar-Hubbe M; de la Garza-Salazar J; Meneses-García A; Astudillo-de la Vega H; Martinez-Said H
J Glob Oncol; 2018 Sep; 4():1-5. PubMed ID: 30241212
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival.
Ito T; Kaku-Ito Y; Murata M; Furue K; Shen CH; Oda Y; Furue M
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32143442
[TBL] [Abstract][Full Text] [Related]
9.
Ren M; Zhang J; Kong Y; Bai Q; Qi P; Zhang L; Wang Q; Zhou X; Chen Y; Zhu X
Ann Transl Med; 2022 Jan; 10(2):31. PubMed ID: 35282092
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Acral Lentiginous Melanoma.
Nakamura Y; Fujisawa Y
Curr Treat Options Oncol; 2018 Jun; 19(8):42. PubMed ID: 29951919
[TBL] [Abstract][Full Text] [Related]
12. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
13. Acral Lentiginous Melanomas Harbour Intratumor Heterogeneity in BRAF Exon 15, With Mutations Distinct From V600E/V600K.
Fernandes M; Barcelos D; Comodo AN; Guimarães DP; Lopes Carapeto FC; Cardili L; de Sousa Morães L; Cerutti Ap J; Landman Ap G
Am J Dermatopathol; 2019 Oct; 41(10):733-740. PubMed ID: 31021835
[TBL] [Abstract][Full Text] [Related]
14.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
15. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
[TBL] [Abstract][Full Text] [Related]
18. BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.
Yilmaz I; Gamsizkan M; Kucukodaci Z; Berber U; Demirel D; Haholu A; Narli G
Indian J Pathol Microbiol; 2015; 58(3):279-84. PubMed ID: 26275246
[TBL] [Abstract][Full Text] [Related]
19. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
20. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
